These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27327616)

  • 1. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
    Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
    PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
    Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
    PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
    Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
    J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
    Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
    Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
    Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
    EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults.
    Turner Overton E; Schmidt D; Vidojkovic S; Menius E; Nopora K; Maclennan J; Weidenthaler H
    Vaccine; 2023 Jan; 41(2):397-406. PubMed ID: 36460535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
    Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
    Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.
    Frey SE; Winokur PL; Hill H; Goll JB; Chaplin P; Belshe RB
    Vaccine; 2014 May; 32(23):2732-9. PubMed ID: 24607004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
    von Sonnenburg F; Perona P; Darsow U; Ring J; von Krempelhuber A; Vollmar J; Roesch S; Baedeker N; Kollaritsch H; Chaplin P
    Vaccine; 2014 Sep; 32(43):5696-702. PubMed ID: 25149431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
    N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
    Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
    Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.
    Overton ET; Stapleton J; Frank I; Hassler S; Goepfert PA; Barker D; Wagner E; von Krempelhuber A; Virgin G; Meyer TP; Müller J; Bädeker N; Grünert R; Young P; Rösch S; Maclennan J; Arndtz-Wiedemann N; Chaplin P
    Open Forum Infect Dis; 2015 Apr; 2(2):ofv040. PubMed ID: 26380340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS.
    Overton ET; Lawrence SJ; Stapleton JT; Weidenthaler H; Schmidt D; Koenen B; Silbernagl G; Nopora K; Chaplin P
    Vaccine; 2020 Mar; 38(11):2600-2607. PubMed ID: 32057574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.
    Greenberg RN; Hurley MY; Dinh DV; Mraz S; Vera JG; von Bredow D; von Krempelhuber A; Roesch S; Virgin G; Arndtz-Wiedemann N; Meyer TP; Schmidt D; Nichols R; Young P; Chaplin P
    PLoS One; 2015; 10(10):e0138348. PubMed ID: 26439129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
    Ilchmann H; Samy N; Reichhardt D; Schmidt D; Powell JD; Meyer TPH; Silbernagl G; Nichols R; Weidenthaler H; De Moerlooze L; Chen L; Chaplin P
    J Infect Dis; 2023 May; 227(10):1203-1213. PubMed ID: 36408618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population.
    Zitzmann-Roth EM; von Sonnenburg F; de la Motte S; Arndtz-Wiedemann N; von Krempelhuber A; Uebler N; Vollmar J; Virgin G; Chaplin P
    PLoS One; 2015; 10(4):e0122653. PubMed ID: 25879867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.